| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
RSV L protein polymerase. PC786 is a non-nucleoside inhibitor of the RSV L protein polymerase.
|
|---|---|
| ln Vitro |
In -2 cells, PC786 was found to exhibit strong and specific antiviral activity against laboratory-adapted or clinically isolated RSV-A (IC50, <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM) by blocking cytotoxic effects. With an IC50 of 0.50±0.0014 nM and an IC90 of 0.63±0.035 nM, PC786 suppresses RSV A2 activity. RSV B WST activity is inhibited by PC786, with IC50 and IC90 values of 27.3±0.77 nM and 57.1±3.87 nM, respectively. When known RSV A clinical isolates are used, PC786 significantly reduces their cytopathic effect (CPE) (IC50, 0.14 to 3.2 nM). A variety of low-passage clinical isolates of RSV A (IC50, 0.42 nM [median]) and RSV B (IC50, 17.5 nM [median]) have been shown to potently suppress CPE when exposed to PC786, as well [1].
In vitro, PC786 demonstrates potent antiviral activity against RSV-A with IC₅₀ values ranging from <0.09 to 0.71 nM. Against RSV-B, the IC₅₀ ranges from 1.3 to 50.6 nM. The compound is a non-nucleoside inhibitor that targets the RSV L protein polymerase, blocking viral replication. |
| ln Vivo |
It was discovered that treating RSV A2-infected BALB/c mice with PC786 intratracheally (it) or intranasally (in) once daily on days 1 through 3 reduced the amount of virus in their lungs. When the drug was administered at 2 mg/mL (40 μg/mouse [approximately 1.6 mg/kg body weight]) or 80 μg/mouse [approximately 3.2 mg/kg] for treatment, the viral loads were below detection thresholds[1].
In vivo, PC786 is an inhaled compound designed for topical antiviral research in airway infection models. It provides a key model for respiratory virus replication inhibition. The compound's localized administration allows for high drug concentrations at the site of infection with reduced systemic exposure. |
| Enzyme Assay |
Non-cell enzyme assays for PC786 are performed using purified RSV L protein polymerase complex. The polymerase activity is measured by the incorporation of [³H]UTP or [³²P]UTP into RNA transcripts. The enzyme complex is incubated with RNA template, nucleotides, and varying concentrations of PC786 (0.001-100 nM) in assay buffer at 37°C for 60 minutes. The reaction is terminated, and incorporated radioactivity is measured by liquid scintillation counting or filter binding. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cellular antiviral assays are performed using HEp-2 or other permissive cell lines infected with RSV-A or RSV-B. Cells are infected at a multiplicity of infection (MOI) of 0.01-0.1 and treated with PC786 at concentrations ranging from 0.001-100 nM. Viral replication is assessed by plaque reduction assay, by measuring viral titers (TCID₅₀) in culture supernatants, or by qPCR for viral RNA. The IC₅₀ for inhibition of viral replication is calculated from dose-response curves. Cytotoxicity is evaluated using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies are conducted in rodent models of RSV infection, such as BALB/c mice. PC786 is administered via inhalation (nebulization or intranasal instillation) at doses determined from pharmacokinetic studies. Efficacy endpoints include viral load in lung tissue (TCID₅₀ or qPCR), histopathological analysis of lung tissue, and inflammatory cytokine levels in bronchoalveolar lavage fluid. The compound's localized antiviral activity is evaluated in airway infection models.
|
| ADME/Pharmacokinetics |
PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. It is a non-nucleoside inhibitor. The compound is designed for localized antiviral activity in airway infection models. Further pharmacokinetic parameters such as half-life, clearance, and lung tissue distribution would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for PC786 are not available in the public domain. As an inhaled compound, potential local effects on the respiratory tract would be a primary safety concern. No significant systemic toxicity has been reported at effective doses. Standard safety pharmacology studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. It is a non-nucleoside inhibitor that targets the RSV L protein polymerase. PC786 demonstrates potent antiviral activity against RSV-A and RSV-B. The compound is not approved for clinical use and is available for research purposes only.
|
| Molecular Formula |
C41H38FN5O4S
|
|---|---|
| Molecular Weight |
715.834931850433
|
| Exact Mass |
715.262
|
| CAS # |
1902114-15-1
|
| PubChem CID |
121276461
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
52
|
| Complexity |
1290
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C(C(NC2C(=CC=CC=2C)F)=O)=CC2=C1C1C=CC=CC=1N(C(C1C=CC(=CC=1)NC(C1=CC(C)=CN=C1N1CC3(CCOCC3)C1)=O)=O)CC2
|
| InChi Key |
VTCJNYICQADBJD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C41H38FN5O4S/c1-25-20-31(37(43-22-25)46-23-41(24-46)15-18-51-19-16-41)38(48)44-29-12-10-27(11-13-29)40(50)47-17-14-28-21-34(52-36(28)30-7-3-4-9-33(30)47)39(49)45-35-26(2)6-5-8-32(35)42/h3-13,20-22H,14-19,23-24H2,1-2H3,(H,44,48)(H,45,49)
|
| Chemical Name |
N-(2-fluoro-6-methylphenyl)-6-[4-[[5-methyl-2-(7-oxa-2-azaspiro[3.5]nonan-2-yl)pyridine-3-carbonyl]amino]benzoyl]-4,5-dihydrothieno[3,2-d][1]benzazepine-2-carboxamide
|
| Synonyms |
PC786; PC 786; PC-786
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~130 mg/mL (~181.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 3.25 mg/mL (4.54 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 3.25 mg/mL (4.54 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.25 mg/mL (4.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3970 mL | 6.9848 mL | 13.9696 mL | |
| 5 mM | 0.2794 mL | 1.3970 mL | 2.7939 mL | |
| 10 mM | 0.1397 mL | 0.6985 mL | 1.3970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
